Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement (MTA) with a pharmaceutical company, referred to as PharmaCO, originally entered into on August 30, 2024. The MTA, which governs the evaluation of Lexaria’s DehydraTECH™ drug delivery technology in a pre-clinical setting, has been extended through December 31, 2026. This extension accommodates the time required for PharmaCO to receive and review Lexaria’s 2026 research and development results related to GLP-1 drugs.
The extension allows both parties to continue their relationship under the MTA, keeping a temporary exclusive license active and in force. It also facilitates additional strategic planning discussions with PharmaCO’s human clinical and business development teams. The collaboration aims to assess the potential of Lexaria’s DehydraTECH technology to improve oral delivery of GLP-1 drugs, which are widely used for diabetes and weight management.
Over the past 12 months, Lexaria has advanced its GLP-1 development program, with progress in three key studies: Human Study #7, Animal Study #1, and Animal Study #2. These studies are fully funded with existing corporate resources and are designed to provide comprehensive evidence to support further collaboration and potential licensing of Lexaria’s technology. Results are expected during the third and fourth quarters of 2026.
DehydraTECH is Lexaria’s patented drug delivery platform that enhances the oral delivery of various drugs by improving bio-absorption, reducing side effects, and enabling some drugs to cross the blood-brain barrier more effectively. The company operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. More information is available at www.lexariabioscience.com.
The extension of the MTA signals continued interest from the pharmaceutical partner in Lexaria’s technology, particularly in the competitive GLP-1 market. Successful results from the ongoing studies could lead to broader licensing agreements and potential revenue streams for Lexaria. The company’s focus on oral drug delivery addresses a key challenge in the pharmaceutical industry, as many drugs require injections or have poor oral bioavailability.
Lexaria’s management emphasized that the extension allows for more thorough evaluation of the data, ensuring that both parties have sufficient time to assess the technology’s potential. The company also noted that the studies are on track and that the collaboration remains a priority. The outcomes of these studies will be critical in determining the next steps for the partnership and the future commercial application of DehydraTECH in the GLP-1 space.
